PRDM16-DT: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: PRDM16-DT

NCBI ID: G440556

PRDM16-DT

Other Name(s): PRDM16 divergent transcript, transcript variant 2 | lnc-dPrdm16 | PRDM16 divergent transcript, transcript variant 1 | LINC00982 | PRDM16 divergent transcript

PRDM16-DT: A Potential Drug Target for Cancer and Neurodegenerative Diseases

PRDM16-DT, also known as PRDM16-Transcript, is a gene that encodes for a protein known as PRDM16. PRDM16 is a core component of the PRDM16 complex, which is a protein-protein interaction network that plays a crucial role in the regulation of gene expression. Mutations in the PRDM16 gene have been linked to a range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The PRDM16 gene has four splice variants, namely PRDM16-DT1, PRDM16-DT2, PRDM16-DT3 and PRDM16-DT4. Among them, the proteins encoded by PRDM16-DT1 and PRDM16-DT2 are different in amino acid sequence, while the proteins encoded by PRDM16-DT3 and PRDM16-DT4 are completely different. These differences make PRDM16-DT1 and PRDM16-DT2 two potential drug targets.

The difference between PRDM16-DT1 and PRDM16-DT2 is mainly reflected in their protein structures. PRDM16 is composed of two subunits, each containing an N-terminal 伪-helix and a C-terminal 尾-sheet. The N-terminal and C-terminal structures of PRDM16-DT1 and PRDM16-DT2 are slightly different. These differences may affect the stability and functionality of PRDM16.

In pharmacological research, PRDM16 has been widely studied as a potential drug target. Mutations in PRDM16-DT1 and PRDM16-DT2 may cause changes in the protein structure, thereby affecting the function of PRDM16. These changes may lead to abnormal expression of PRDM16 in cells, leading to the occurrence of a series of diseases.

Currently, PRDM16-DT1 and PRDM16-DT2 have been confirmed as potential drug targets by multiple research teams. These studies explored the application of PRDM16-DT1 and PRDM16-DT2 in drug screening and drug design. At the same time, these studies also deeply studied the roles of PRDM16-DT1 and PRDM16-DT2 in diseases, including tumorigenesis, neurodegenerative diseases, and autoimmune diseases.

Mutations in PRDM16-DT1 and PRDM16-DT2 may also contribute to their importance in biomedical research. By studying mutations in PRDM16, scientists can better understand PRDM16's role in gene expression and disease. These studies can provide important theoretical guidance for drug research and development and provide new ideas for the treatment of diseases.

In summary, PRDM16-DT is a gene worthy of attention, and its importance in drug research and biomedical research is increasingly prominent. By in-depth study of PRDM16 mutations, scientists can better understand the role of PRDM16 in gene expression and disease, and provide new ideas for drug development and disease treatment.

Protein Name: PRDM16 Divergent Transcript

The "PRDM16-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRDM16-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets